# American Vanguard Corp: Form 10-Q for the period ended Jun 30, 2019

- Company: [American Vanguard Corp](/companies/avd.md) (CIK 5981)
- Form: 10-Q
- Filed: 2019-08-07
- Accepted by EDGAR: Aug 7, 2019, 13:48 ET
- Period: 2019-06-30
- Accession: 0001564590-19-029861
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/5981/000156459019029861/avd-10q_20190630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/5981/000156459019029861/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-04-01 to 2019-06-30 | $113.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2019-01-01 to 2019-06-30 | $212.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-04-01 to 2019-06-30 | $71.5m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2019-01-01 to 2019-06-30 | $129.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-04-01 to 2019-06-30 | $41.7m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2019-01-01 to 2019-06-30 | $83.4m | us-gaap:GrossProfit |
| Operating income | 3 months, 2019-04-01 to 2019-06-30 | $6.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2019-01-01 to 2019-06-30 | $13.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-04-01 to 2019-06-30 | $1.9m | us-gaap:InterestExpense |
| Interest expense | 6 months, 2019-01-01 to 2019-06-30 | $3.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-04-01 to 2019-06-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2019-01-01 to 2019-06-30 | $2.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-04-01 to 2019-06-30 | $3.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2019-01-01 to 2019-06-30 | $7.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-04-01 to 2019-06-30 | $0.11 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2019-01-01 to 2019-06-30 | $0.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-04-01 to 2019-06-30 | $0.11 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2019-01-01 to 2019-06-30 | $0.24 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-04-01 to 2019-06-30 | 29,540,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2019-01-01 to 2019-06-30 | 29,560,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2019-01-01 to 2019-06-30 | −$32.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 6 months, 2019-01-01 to 2019-06-30 | $1.2m | us-gaap:PaymentsOfDividends |
| Share repurchases | 6 months, 2019-01-01 to 2019-06-30 | $2.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-06-30 | $6.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-06-30 | $342.9m | us-gaap:AssetsCurrent |
| Total assets | at 2019-06-30 | $665.8m | us-gaap:Assets |
| Current liabilities | at 2019-06-30 | $129.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-06-30 | $332.0m | us-gaap:Liabilities |
| Long-term debt | at 2019-06-30 | $164.6m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2019-06-30 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2019-06-30 | $333.8m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 40,334 characters.

### FORWARD-LOOKING STATEMENTS/RISK FACTORS:

The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

### MANAGEMENT OVERVIEW

The Company’s overall operating results for the three months ended June 30, 2019 were mixed versus those of the same period of 2018. Quarterly net sales were up about 6% ($113,104 v $107,046), while gross profit was down approximately 4% ($41,653 v $43,297). Gross margin declined to 37% from 40% of net sales, and operating expenses rose by approximately 2% ($35,362 v $34,718), but declined as a percent of net sales from 32% to 31%. Net income attributable to American Vanguard was down about 46% ($3,106 v. $5,599).

Broadly speaking, during the second quarter of 2019, the Company’s international sales continued to grow, while domestic sales were flat. Within that performance, quarterly net sales of our non-crop product lines grew significantly, due largely to pest strips and to mosquito products (in light of wet weather). However, these gains were offset by declines in crop product sales, as record precipitation and cold weather delayed, and in some cases prevented, normal crop planting throughout the Midwest and Southeast regions of the United States. Many growers had insufficient time to use the normal measure of pre-plant crop inputs, others were unable to fully plant their intended acreage, and many of the acres that were planted are likely to produce below average yields. By contrast, with solid sales in Central America and the addition of sales from our newly acquired business in Brazil, our international business recorded higher sales during the period.

Gross margin as a percent of sales dropped by 3% due largely to lower factory utilization for the period. During the second quarter of 2018, factory activity was at a record pace and, by contrast, factory under absorption during second quarter of 2019 amounted to approximately 3.5% of sales, which is closer to the Company’s long-term strategic manufacturing plan. Quarterly operating expenses, while higher for the period, were lower as a percent of net sales, as the Company continues to realize greater economies of scale in its global business. This change in operating expense included costs necessary to manage the products and businesses acquired at the end of 2018 and during the first six months of 2019. Furthermore, the Company recorded increased interest expense, as compared to the same period of the prior year, reflecting borrowings related to acquisition activity in the second half of 2018 and the first half of 2019. These factors, together, yielded a decrease in net income of $2,493 for the quarter.

The Company’s overview of sales and gross margin performance for the three months ended June 30, 2019 and 2018 is as follows:

| Net sales: | For the three months ended June 30, 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US crop | $47,311 | $51,760 | $(4,449) | -9% |
| US non-crop | 17,219 | 12,603 | 4,616 | 37% |
| US total | 64,530 | 64,363 | 167 | 0% |
| International | 48,574 | 42,683 | 5,891 | 14% |
| Net sales: | $113,104 | $107,046 | $6,058 | 6% |
| Gross profit: |  |  |  |  |
| US crop | $18,719 | $26,222 | $(7,503) | -29% |
| US non-crop | 8,558 | 6,352 | 2,206 | 35% |
| US total | 27,277 | 32,574 | (5,297) | -16% |
| International | 14,376 | 10,723 | 3,653 | 34% |
| Total gross profit: | $41,653 | $43,297 | $(1,644) | -4% |
| Gross margin domestic | 42% | 51% |  |  |
| Gross margin international | 30% | 25% |  |  |
| Gross margin total | 37% | 40% |  |  |

Our US Crop business recorded 9% lower sales in the three months ended June 30, 2019, as compared to the same period of the prior year. Among our granular soil insecticides, sales of Aztec were up about 26% over the prior year period, as distributors and retailers replenished channel inventories. These dynamics were offset by decreased sales of Counter and Thimet, largely due to wet conditions in the Midwest and Southeast regions of the United States. Sales of our Impact post-emergent corn herbicide, used primarily on row crops, our Dacthal product line, used on high-value vegetable crops, and our Parazone products, used for burn down prior to the start of the season, remained flat to slightly up versus last year, while wet conditions negatively affected demand for Abba herbicide used in tree nut applications.

Net sales of our US non-crop business increased about 37% to $17,219 from $12,603, quarter-over-quarter. This result was due largely to increased sales of our aerial applied mosquito adulticide, Dibrom, as applicators restocked both to address persistent wet weather conditions in the U.S. and to prepare for potential hurricane activity later in 2019. Sales of both our pest strips and our pharmaceutical products increased as compared to the same period of 2018.

Net sales of our international businesses were up nearly 14% during the period ($48,574 v $42,683). A significant part of this increase was due to the addition of sales from our newly acquired Brazilian subsidiaries, Defensive and Agrovant, and the addition of our Assure II herbicide products that were acquired in December 2018. Performance in Brazil met our expectations, despite drought conditions and competitive pressure in certain markets. We experienced solid sales performance from AgriCenter in Central America – with higher granular soil insecticide sales, steady demand for fungicides and miscellaneous products, and somewhat lower foliar insecticide sales. Elsewhere in the international sector, we posted increased sales of Mocap insecticide and bromacil herbicides (despite continuing supply shortages) during this period, while both Nemacur and Thimet sales declined as the result of various weather-related issues. A more detailed explanation of net sales, markets and factors affecting profitability appears below.

### RESULTS OF OPERATIONS

### Quarter Ended June 30, 2019 and 2018:

| Net sales: | 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $36,509 | $38,496 | $(1,987) | -5% |
| Herbicides/soil fumigants/fungicides | 37,203 | 34,747 | 2,456 | 7% |
| Other, including plant growth regulators | 22,173 | 21,200 | 973 | 5% |
| Total crop | 95,885 | 94,443 | 1,442 | 2% |
| Non-crop | 17,219 | 12,603 | 4,616 | 37% |
|  | $113,104 | $107,046 | $6,058 | 6% |
| Cost of sales: |  |  |  |  |
| Insecticides | $22,392 | $23,560 | $(1,168) | -5% |
| Herbicides/soil fumigants/fungicides | 24,204 | 19,947 | 4,257 | 21% |
| Other, including plant growth regulators | 16,194 | 13,991 | 2,203 | 16% |
| Total crop | 62,790 | 57,498 | 5,292 | 9% |
| Non-crop | 8,661 | 6,251 | 2,410 | 39% |
|  | $71,451 | $63,749 | $7,702 | 12% |
| Gross profit: |  |  |  |  |
| Insecticides | $14,117 | $14,936 | $(819) | -5% |
| Herbicides/soil fumigants/fungicides | 12,999 | 14,800 | (1,801) | -12% |
| Other, including plant growth regulators | 5,979 | 7,209 | (1,230) | -17% |
| Gross profit crop | 33,095 | 36,945 | (3,850) | -10% |
| Gross profit non-crop | 8,558 | 6,352 | 2,206 | 35% |
|  | $41,653 | $43,297 | $(1,644) | -4% |
| Gross margin crop | 35% | 39% |  |  |
| Gross margin non-crop | 50% | 50% |  |  |
| Total gross margin | 37% | 40% |  |  |

| Net sales: | 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $64,530 | $64,363 | $167 | 0% |
| International | 48,574 | 42,683 | 5,891 | 14% |
|  | $113,104 | $107,046 | $6,058 | 6% |

Across our crop business, net sales of our insecticides group were down approximately 5% to end at $36,509, as compared to $38,496 during the second quarter of 2018. Within this category, net sales of our non-granular insecticides were aided by our cotton insecticide Bidrin®, which posted higher sales due to higher pest pressure. Net sales of our granular soil insecticides were down approximately 4% due to the weaker performance of our Thimet® (used primarily in peanuts and sugar cane) and Counter (used in corn and sugar beets) largely resulting from weather-related applications challenges. Offsetting this was an increase in Aztec corn soil insecticide sales, as mentioned above.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the second quarter of 2019 increased by approximately 7% to $37,203 from $34,747 in the comparable period of 2018. Net sales of our herbicide products increased approximately 38%, largely due to the addition of the Assure II products purchased in December of 2018. Sales of our post-emergent corn herbicide Impact®, Dacthal® for use on a wide variety of high valued vegetable crops, and our Paraquat burn-down product, all posted flat to slightly increased sales relative to the second quarter of 2018. We also enjoyed increased sales of our international bromacil products Hyvar® and Krovar®. In fungicides, we posted significantly lower sales of chlorothalonil due to abnormally high supply (from expedited, pre-tariff importation of large quantities by many sellers) and pricing pressure in the face of seasonally normal demand.

Within the group of other products (which includes Defensive and Agrovant, parts of the AgriCenter business, plant growth regulators, molluscicides and tolling activity), net sales increased 5%, to $22,173, as compared to $21,200 for the second quarter of 2018. Lower quarterly sales of our Folex® cotton defoliant resulted from shipment delays; however, increased usage is anticipated in the third quarter for harvest defoliation.

Our non-crop sales ended the second quarter of 2019 up 37% at $17,219, as compared to $12,603, for the same period of the prior year. This result was driven largely by increased quarterly sales of our aerial applied Dibrom mosquito adulticide, along with a strong increase in pest strip sales and a modest increase in our OHP horticultural business.

Our international business performed strongly and increased sales by 14%, ending at $48,574, as compared to $42,683 for the second quarter of the prior year. The main growth drivers related to products acquired at the end of 2018 and the Brazilian businesses acquired during 2019. Both business lines contributed strongly to sales growth and overall improvement in gross profit performance.

Our cost of sales for the second quarter of 2019 was $71,451 or 63% of sales. This compared to $63,749 or 60% of sales for the same period of 2018. The increase in cost of sales as a percentage of net sales in 2019 is driven by decisions made to reduce factory output of our Thimet and Counter products in order to reduce those inventories during 2019 responding to lower than expected sales as noted above. Furthermore, cost of goods was affected by a change in product mix, including the effect of acquired products and distribution businesses, which drive high sales at comparatively lower margins than our pre-existing business.

Gross profit for the second quarter of 2019 decreased by $1,644, or 4%, to end at $41,653, as compared to $43,297 for the second quarter of 2018. Gross margin percentage ended at 37% in the three months ended June 30, 2019, as compared to 40% in the same period of the prior year. As previously noted, the change in performance is largely driven by decision made to manage factory output and inventory levels and the new products and businesses acquired in late 2018 and year to date in 2019.

Operating expenses increased by $644 to $35,362 for the three months ended June 30, 2019, as compared to the same period in 2018. The differences in operating expenses by department are as follows:

|  | 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $11,770 | $10,617 | $1,153 | 11% |
| General and administrative | 9,182 | 9,522 | (340) | -4% |
| Research, product development and regulatory | 6,856 | 7,286 | (430) | -6% |
| Freight, delivery and warehousing | 7,554 | 7,293 | 261 | 4% |
|  | $35,362 | $34,718 | $644 | 2% |

- Selling expenses increased by $1,153 to end at $11,770 in the three months ended June 30, 2019 as compared to the same period of the prior year. This is mainly resulted from increased sales activities associated with the newly acquired distribution businesses.
- General and administrative expenses decreased by $340 to end at $9,182 for the three months ended June 30, 2019, as compared to the same period of 2018. The main drivers for the decrease are the decrease in legal activities of $1,000 associated with the Takings case, income of $500 from a breakup fee associated with a potential acquisition and reduced reserves for receivables by $407. These decreases were offset by the costs associated with products and businesses acquired in late 2018 and early 2019.
- Research, product development costs and regulatory expenses decreased by $430 to end at $6,856 for the three months ended June 30, 2019, as compared to the same period of 2018. The main drivers were decreases in our product defense and product development costs.
- Freight, delivery and warehousing costs for the three months ended June 30, 2019 were $7,554 or 6.7% of sales as compared to $7,293 or 6.8% of sales for the same period in 2018. The increased cost was associated with the increase in sales recorded in the second quarter of 2019, as compared to the same period of 2018 and the mix of those sales.

Interest costs net of capitalized interest were $1,925 in the three months ended June 30, 2019, as compared to $966 in the same period of 2018. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Three months ended June 30, 2019 Average Debt | Interest Expense | Interest Rate | Three months ended June 30, 2018 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $178,616 | $1,908 | 4.3% | $100,928 | $878 | 3.5% |
| Amortization of deferred loan fees | — | 53 | — | — | 58 | — |
| Amortization of other deferred liabilities | — | — | — | — | 52 | — |
| Other interest (income) expense | — | 47 | — | — | (5) | — |
| Subtotal | 178,616 | 2,008 | 4.5% | 100,928 | 983 | 3.9% |
| Capitalized interest | — | (83) | — | — | (17) | — |
| Total | $178,616 | $1,925 | 4.3% | $100,928 | $966 | 3.8% |

The Company’s average overall debt for the three months ended June 30, 2019 was $178,616, as compared to $100,928 for the three months ended June 30, 2018. During the quarter, we continued to focus on managing our working capital for our expanded business and controlling our usage of revolving debt. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 4.3% for the three months ended June 30, 2019, as compared to 3.5% in 2018.

Income tax expense was $1,224 for the three months ended June 30, 2019, as compared to $1,748 for the comparable period in 2018. The effective tax rate for the quarter was 28%, as compared to 23% in the same period of the prior year. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management. The increase in effective tax rate is primarily driven by the mix of our domestic and international income.

During the three months ended June 30, 2019 and 2018, we recognized gains of $36 and $46, respectively, on our investment in the Hong Kong joint venture, which is a 50% owned equity investment. Furthermore, during the three months ended June 30, 2018, we recognized a loss of $347 on our investment in TyraTech. TyraTech became a wholly owned and consolidated subsidiary on November 9, 2018.

Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance. During the three months ended June 30, 2018, non-controlling interest amounted to a gain of $35. Envance became a wholly owned subsidiary on November 9, 2018.

Our overall net income for the three months ended June 30, 2019 was $3,106 or $0.11 per basic and diluted share, as compared to $5,599 or $0.19 per basic and diluted share in the same period of 2018.

### Six Months Ended June 30 2019 and 2018:

The Company’s overall operating results for the first half of 2019 were flat or down, as compared to those of the same period of 2018. Six month net sales were essentially flat ($212,780 v $211,154), gross profit was down slightly ($83,355 v 84,348), and gross margin declined to 39% from 40% of net sales. Operating expenses rose by approximately 3% ($70,162 v $68,418) and increased as a percent of net sales to 33% from 32%. Net income was down about 32% ($7,012 v. $10,254).

Gross margin as a percent of sales dropped by 1% during the first half of 2019, due largely to lower factory utilization for the period. Operating expenses during the six-month period increased primarily as a result of the addition of products and businesses acquired in late 2018 and year to date in 2019. Further, we recorded higher interest expense, arising from borrowing due largely to acquisition activity in 2018 and 2019. These factors, together, resulted in a decrease in net income of $3,242 for the first half of the year. A more detailed explanation of net sales, markets and factors affecting profitability appears below.

The Company’s overview of sales and gross margin performance for the six months ended June 30, 2019 and 2018 is as follows:

| Net sales: | For the six months ended June 30, 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US crop | $96,560 | $108,785 | $(12,225) | -11% |
| US non-crop | 29,507 | 25,393 | 4,114 | 16% |
| US total | 126,067 | 134,178 | (8,111) | -6% |
| International | 86,713 | 76,976 | 9,737 | 13% |
| Net sales: | $212,780 | $211,154 | $1,626 | 1% |
| Gross profit: |  |  |  |  |
| US crop | $42,214 | $50,753 | $(8,539) | -17% |
| US non-crop | 14,872 | 12,432 | 2,440 | 20% |
| US total | 57,086 | 63,185 | (6,099) | -10% |
| International | 26,269 | 21,163 | 5,106 | 24% |
| Total gross profit: | $83,355 | $84,348 | $(993) | -1% |
| Gross margin domestic | 45% | 47% |  |  |
| Gross margin international | 30% | 27% |  |  |
| Gross margin total | 39% | 40% |  |  |

Our US crop business recorded net sales that were about 11% below those of first half of 2018 ($96,560 v $108,795). Among our granular soil insecticides, sales of Aztec were up about 14% over the prior year period, as distributors and retailers replenished channel inventories. This increase was partially offset by decreased sales of Counter and Thimet, largely due to wet conditions in the Midwest and Southeast regions of the United States. Sales of our Impact post-emergent corn herbicide were up year-over-year, as inclement weather prevented many growers from applying a full measure of pre-emergent herbicides prior to planting. Dacthal, used on high-value vegetable crops, was slightly down in comparison to a very strong prior year. Our Parazone herbicide product sales were down due to persistent wet weather in key markets and higher-than-normal channel inventory.

Net sales of our domestic non-crop business increased about 16% to $29,507 from $25,393, period-over-period. This result was due largely to strong sales of our pest strips, our pharmaceutical products, sales from Envance and additional sales of our mosquito adulticide Dibrom, as applicators restocked both to address persistent wet weather conditions in the U.S. and to prepare for potential hurricane activity later in 2019.

Net sales of our international businesses were up approximately 13% during the period ($86,713 v $76,976). A significant part of this increase was due to the addition of sales from our newly acquired Brazilian subsidiaries, Defensive and Agrovant, and the addition of our Assure II herbicide products that were acquired in December 2018. Performance in Brazil met our expectations, despite drought conditions and competitive pressure in certain markets. We experienced solid sales performance from AgriCenter in Central America – with higher granular soil insecticide sales, steady demand for fungicides and miscellaneous products, and somewhat lower foliar insecticide sales. Elsewhere in the international sector, we posted increased sales of Mocap insecticide and bromacil herbicides (despite continuing supply shortages) during this period, while both Nemacur and Thimet sales declined as the result of various weather-related issues. A more detailed explanation of net sales, markets and factors affecting profitability appears below.

### RESULTS OF OPERATIONS

### Six months ended June 30, 2019 and 2018

| Net sales: | 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Insecticides | $76,692 | $84,654 | $(7,962) | -9% |
| Herbicides/soil fumigants/fungicides | 68,738 | 71,262 | (2,524) | -4% |
| Other, including plant growth regulators | 37,843 | 29,845 | 7,998 | 27% |
| Total crop | 183,273 | 185,761 | (2,488) | -1% |
| Non-crop | 29,507 | 25,393 | 4,114 | 16% |
| Total net sales | $212,780 | $211,154 | $1,626 | 1% |
| Cost of sales: |  |  |  |  |
| Insecticides | $45,330 | $52,501 | $(7,171) | -14% |
| Herbicides/soil fumigants/fungicides | 43,064 | 42,176 | 888 | 2% |
| Other, including plant growth regulators | 26,396 | 19,168 | 7,228 | 38% |
| Total crop | 114,790 | 113,845 | 945 | 1% |
| Non-crop | 14,635 | 12,961 | 1,674 | 13% |
| Total cost of sales | $129,425 | $126,806 | $2,619 | 2% |
| Gross profit: |  |  |  |  |
| Insecticides | $31,362 | $32,153 | $(791) | -2% |
| Herbicides/soil fumigants/fungicides | 25,674 | 29,086 | (3,412) | -12% |
| Other, including plant growth regulators | 11,447 | 10,677 | 770 | 7% |
| Gross profit crop | 68,483 | 71,916 | (3,433) | -5% |
| Gross profit non-crop | 14,872 | 12,432 | 2,440 | 20% |
| Total gross profit | $83,355 | $84,348 | $(993) | -1% |
| Gross margin crop | 37% | 39% |  |  |
| Gross margin non-crop | 50% | 49% |  |  |
| Total gross margin | 39% | 40% |  |  |

| Net sales: | 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| US | $126,067 | $134,178 | $(8,111) | -6% |
| International | 86,713 | 76,976 | 9,737 | 13% |
| Total net sales | $212,780 | $211,154 | $1,626 | 1% |

Across our crop business, net sales of our insecticides group declined approximately 9% to end at $76,692, as compared to $84,654 during the six months ended June 30, 2018. Within this category, net sales of our non-granular insecticides were driven by our cotton insecticide Bidrin®, which posted a 50% sales gain due to increased year-over-year cotton acres in the U.S. This increase more than offset sales declines of Abamectin resulting from regional weather issues and bifenthrin resulting from generic competitive pressures. Net sales of our granular soil insecticides were down about 14% due to lower Thimet sales in peanuts, lower sales of Counter in sugar beets, and lower sales internationally for Mocap and Nemacur, in part due to regulatory concerns.

Within the group of herbicides/fungicides/fumigants used in crop applications, net sales for the six months ended June 30, 2019 decreased by approximately 4% to $68,738 from $71,262, in the comparable period of 2018. While our traditional Impact and Dacthal products had stable results, the decrease in this group was driven by reduced sales of chlorothalonil due to abnormally high supply (from expedited, pre-tariff importation of large quantities by many sellers) and pricing pressure in the face of seasonally normal demand. Additionally, wet weather inhibited the application of our Parazone burn-down herbicide and Metam soil fumigants. Offsetting these declines were the addition of the Assure II herbicide acquired at the end of 2018 and year-over-year increases in our bromacil herbicides, both of these factors were largely reflected in the international section of our business.

Within the group of other products (which includes part of our AgriCenter business, the Defensive and Agrovant Brazilian subsidiaries, plant growth regulators, molluscicides and tolling activity), net sales were $37,843, up approximately 27%, as compared to $29,845 in the first half of 2018. This result benefitted from the inclusion of the Brazilian business, modest gains in the AgriCenter business and improved sales of our growth regulator NAA. These items offset lower half-year sales of our Folex® cotton defoliant and reduced toll manufacturing activity.

Our non-crop sales ended the first half of 2019 with net sales of $29,507 up 16%, as compared to $25,393 for the same period of the prior year. This category benefitted from continued strong sales of our aerially-applied mosquito adulticide Dibrom, commercial pest control products including pest strips, the OHP horticulture business, and our pharmaceutical products.

Our first half International sales ended at $86,713, a 13% increase over the $76,976 in the first six month of 2018. The main driver of this performance was the addition of the Defensive and Agrovant businesses in Brazil, the AgriCenter Central American business, and the acquisition of the Assure II products at the end of 2018. Our traditional product portfolio (including Mocap, Nemacur) showed significant half-year sales declines within the international markets.

Our cost of sales for the first half of 2019 ended at $129,425 or 61% of net sales. This compares to $126,806 or 60% of net sales in the same period of 2018. The increase in cost of sales as a percentage of net sales in 2019 was driven in part by decisions made to reduce factory output as part of our 2019 manufacturing plan.

Gross profit for the six months ended June 30, 2019 decreased by $993, or 1%, to end at $83,355, as compared to $84,348 for the first half of 2018. Gross margin percentage ended at 39% in the first six months of 2019, as compared to 40% in the same period of the prior year. As previously noted, the change in performance is largely driven by the Company updated manufacturing plan for 2019 which responds to the weather related lower sales already discussed and the new businesses acquired in early 2019.

Operating expenses increased by $1,744 to $70,162 for the six months ended June 30, 2019, as compared to the same period in 2018. The differences in operating expenses by department are as follows:

|  | 2019 | 2018 | Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Selling | $22,697 | $20,060 | $2,637 | 13% |
| General and administrative | 20,473 | 20,686 | (213) | -1% |
| Research, product development and regulatory | 12,539 | 13,563 | (1,024) | -8% |
| Freight, delivery and warehousing | 14,453 | 14,109 | 344 | 2% |
|  | $70,162 | $68,418 | $1,744 | 3% |

- Selling expenses increased by $2,637 to end at $22,697 for the six months ended June 30, 2019, as compared to the same period of 2018. The main driver was an increase in activities from the newly acquired businesses during 2018 and 2019 and by increased spending on advertising for our domestic market.
- General and administrative expenses decreased by $213 to end at $20,473 for the six months ended June 30, 2019, as compared to the same period of 2018. The main drivers for the decrease are the decrease in legal activities of $1,000 associated with the Takings case, adjustments to estimates for deferred consideration in the amount of $2,888, as compared to $1,468 for the same period of the prior year and income of $500 from a breakup fee associated with a potential acquisition. These decreases were partially offset by the increase in costs associated with newly acquired products and businesses.
- Research, product development costs and regulatory expenses decreased by $1,024 to end at $12,539 for the six months ended June 30, 2019, as compared to the same period of 2018. The main drivers were decreases in our product defense and product development costs.
- Freight, delivery and warehousing costs for the six months ended June 30, 2019 were $14,453 or 6.8% of sales as compared to $14,109 or 6.6% of sales for the same period in 2018.

Interest costs net of capitalized interest were $3,537 in the first six months of 2019, as compared to $1,803 in the same period of 2018. Interest costs are summarized in the following table:

### Average Indebtedness and Interest expense

|  | Six months ended June 30, 2019 Average Debt | Interest Expense | Interest Rate | Six months ended June 30, 2018 Average Debt | Interest Expense | Interest Rate |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revolving line of credit (average) | $160,782 | $3,485 | 4.3% | $94,934 | $1,577 | 3.3% |
| Amortization of deferred loan fees | — | 103 | — | — | 117 | — |
| Amortization of other deferred liabilities | — | — | — | — | 154 | — |
| Other interest (income) expense | — | 59 | — | — | (11) | — |
| Subtotal | 160,782 | 3,647 | 4.5% | 94,934 | 1,837 | 3.9% |
| Capitalized interest | — | (110) | — | — | (34) | — |
| Total | $160,782 | $3,537 | 4.4% | $94,934 | $1,803 | 3.8% |

The Company’s average overall debt for the six months ended June 30, 2019 was $160,782, as compared to $94,934 for the six months ended June 30, 2018. During the period, we continued to focus on our usage of revolving debt, while funding working capital for the newly acquired products and businesses. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 4.3% for the six months ended June 30, 2019, as compared to 3.3% in 2018.

Income tax expense was $2,584 for the six months ended June 30, 2019, as compared to $3,440 for the comparable period in 2018. The effective tax rate for the six months ended June 30, 2019 was 26.8%, as compared to 24.4% in the same period of the prior year. Our effective tax rate increased due to the Company’s mix of domestic and international business. Furthermore, the effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

During the six months ended June 30, 2019 and 2018, the Company recognized losses of $60 and $75, respectively, on our investment in the Hong Kong joint venture which is a 50% owned equity investment. During the six months ended June 30, 2018, we recognized a loss of $443 on our investment in TyraTech. TyraTech became a wholly owned and consolidated subsidiary on November 9, 2018.

Non-controlling interest represents the share of net income or loss that is attributable to the minority stockholder of our majority owned subsidiary, Envance. During the six months ended June 30, 2018, non-controlling interest amounted to a gain of $85. Envance became a wholly owned subsidiary on November 9, 2018.

Our overall net income for the six months ended June 30, 2019 was $7,012 or $0.24 per basic and diluted share, as compared to $10,254 or $0.35 per basic and $0.34 per diluted share in the same period of 2018.

### LIQUIDITY AND CAPITAL RESOURCES

The Company used cash of $32,086 in operating activities during the six months ended June 30, 2019, as compared to $3,804 provided by operating activities during the six months ended June 30, 2018. Included in the $32,086 are net income of $7,012, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $11,379, stock based compensation of $2,995, revision of deferred compensation of $2,888, changes in deferred income taxes of $572 and losses from equity method investments of $60. The total provided net cash inflows of $18,431, as compared to $24,299 for the same period of 2018.

During the first six months of 2019, the Company increased working capital by $48,935, as compared to $19,172 during the same period of the prior year. Included in this change: inventories increased by $27,635, driven by our expanded business as we work through the annual industry cycle. Deferred revenue decreased by $19,438, as compared to $7,254 in the same period of 2018, driven by customer decisions regarding product demand, payment timing and our cash incentive programs. Our accounts payable balances decreased by $10,138 reflecting decisions to work down inventory as part of our integrated manufacturing plan and the impact of new business cycles associated with our distribution businesses. This compared with an increase of $11,309 in the same period of 2018. Accounts receivables decreased by $7,841 as compared to $5,297 in the same period of 2018, with the change driven primarily by a different mix of domestic crop sales (and associated timing and terms) following the purchases of new products in 2018. Prepaid expenses increased by $1,844 and income tax receivable decreased by $4,480. Accrued programs increased by $11,823, as compared to $15,039 in the prior year. Finally, other payables and accrued expenses decreased by $6,719, as compared to $3,683 in the prior year, as a result of the incentive compensation accrual.

With regard to our program accrual, the change primarily reflects our mix of sales and customers in the first half of 2019, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first half of 2019, the Company made accruals for programs in the amount of $29,220 and made payments in the amount of $17,397. During the first half of 2018, the Company made accruals in the amount of $28,813 and made payments in the amount of $13,774. The increased payments in 2019 relate to the mix of products sold during the period and associated variations in payment cycles.

Cash used for investing activities was $31,518 for the six months ended June 30, 2019, as compared to $4,861 for the six months ended June 30, 2018. The Company spent $7,216 on capital expenditures primarily focused on continuing to invest in manufacturing infrastructure and $24,302 related to a business acquisition during 2019.

The Company has a revolving line of credit that is shown as long-term debt in the condensed consolidated balance sheets at June 30, 2019 and December 31, 2018. These are summarized in the following table:

| Long-term indebtedness ($000's) | June 30, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Revolving line of credit | $165,200 | $97,400 |
| Deferred loan fees | (626) | (729) |
| Net long-term debt | $164,574 | $96,671 |

As of June 30, 2017, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company, AMVAC CV and AMVAC BV), as guarantors and/or borrowers, entered into a Third Amendment to Second Amended and Restated Credit Agreement (the “Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and Letter of Credit (“L/C”) issuer. The Credit Agreement is a senior secured lending facility, consisting of a line of credit of up to $250,000, an accordion feature of up to $100,000 and a maturity date of June 30, 2022. The Credit Agreement contains two key financial covenants; namely, borrowers are required to maintain a Consolidated Funded Debt Ratio of no more than 3.25-to-1 and a Consolidated Fixed Charge Covenant Ratio of at least 1.25-to-1. The Company’s borrowing capacity varies with its financial performance, measured in terms of EBITDA, for the trailing twelve month period. Under the Credit Agreement, revolving loans bear interest at a variable rate based, at borrower’s election with proper notice, on either (i) LIBOR plus the “Applicable Rate” which is based upon the Consolidated Funded Debt Ratio (“Eurocurrency Rate Loan”) or (ii) the greater of (x) the Prime Rate, (y) the Federal Funds Rate plus 0.50%, and (z) the Daily One-Month LIBOR Rate plus 1.00%, plus, in the case of (x), (y) or (z) the Applicable Rate (“Alternate Base Rate Loan”). Interest payments for Eurocurrency Rate Loans are payable on the last day of each interest period (either one, two, three or six months, as selected by the borrower) and the maturity date, while interest payments for Alternate Base Rate Loans are payable on the last business day of each month and the maturity date.

At June 30, 2019, according to the terms of the Credit Agreement and based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $30,557. This compares to an available borrowing capacity of $137,047 as of June 30, 2018. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for trailing twelve-month period plus proforma basis arising from acquisitions, which have declined, (2) net borrowings, which have increased due to recent acquisitions and (3) the leverage covenant (being the number of times EBITDA the Company may borrow under its credit facility agreement).

We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.

### RECENTLY ISSUED ACCOUNTING GUIDANCE

Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued accounting standards.

### CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2018, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2018, except for the adoption of ASC 842, Leases, as of January 1, 2019.

Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the condensed consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.

## Market risk

As filed, 1,252 characters.

The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2018.

The Company conducts business in various foreign currencies, primarily in Europe, Mexico, Central and South America. Therefore changes in the value of the currencies of such countries or regions affect the Company’s financial position and cash flows when translated into U.S. Dollars. The Company has mitigated and will continue to mitigate a portion of its currency exchange exposure through natural hedges based on the operation of decentralized foreign operating companies in which the majority of all costs are local-currency based. Furthermore, the Company has established a procedure for covering forward exchange rates on specific purchase orders when appropriate. A 10% change in the value of all foreign currencies would have an immaterial effect on the Company’s financial position and cash flows.

## Controls and procedures

As filed, 1,227 characters.

As of June 30, 2019, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of June 30, 2019, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.

There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. We implemented internal controls to ensure we adequately evaluated our contracts and properly assessed the impact of the new accounting standards under ASC 842, *Leases.*

### PART II. OTHER INFORMATION

The Company was not required to report any matters or changes for any items of Part II except as disclosed below.

## Risk factors

As filed, 2,027 characters.

The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2018, filed on March 12, 2019. In preparing this document, we have reviewed all the risk factors included in that document and have identified two areas that warrant disclosure in this filing.

***Product liability judgments on glyphosate by domestic courts present a litigation risk to companies in this industry. –*** Over the past several months, multiple judgments have been rendered by domestic courts in product liability cases against Bayer/Monsanto in connection with injuries allegedly arising from exposure to the herbicide product, glyphosate. The basis was purported carcinogenicity based largely upon the findings of certain international organizations, in spite of significant scientific evidence to the contrary. While the Company has not sold glyphosate domestically, the theory of these results could put one or more of the Company’s products at risk. There is no guarantee that one or more product liability actions would not be brought against the Company on a similar basis. Further, adverse rulings in such actions could have a material adverse affect upon the Company’s financial performance in future reporting periods.

***The trend of passing pesticide “ban-bills” in various states could put one or more of the Company’s products at risk. –*** In certain states, including Maryland and New York, state and/or local legislatures have passed legislation banning the use of chlorpyrifos, in spite of valid registrations at USEPA and/or the equivalent state agency. While the Company does not sell chlorpyrifos products, there is no guarantee that one or more of its registered products would not be targeted in state or local legislation of this nature. Further, such legislation could have a material adverse effect upon the Company’s financial performance in future reporting periods.

Filed Aug 7, 2019.
Source: SEC EDGAR, the filing index for accession 0001564590-19-029861. Last ingested by Listed: Nov 11, 2026, 00:16 ET. No prices; not investment advice.
